Patents Assigned to Da Volterra
-
Patent number: 11365403Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.Type: GrantFiled: October 24, 2018Date of Patent: June 21, 2022Assignees: Da Volterra, BioasterInventors: Jean De Gunzburg, Jean-Denis Docquier
-
Publication number: 20220087945Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.Type: ApplicationFiled: November 11, 2021Publication date: March 24, 2022Applicant: Da VolterraInventors: Francois LESCURE, Jean DE GUNZBURG
-
Patent number: 11202761Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.Type: GrantFiled: July 26, 2018Date of Patent: December 21, 2021Assignee: DA VOLTERRAInventors: Francois Lescure, Jean De Gunzburg
-
Patent number: 10988749Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.Type: GrantFiled: February 22, 2017Date of Patent: April 27, 2021Assignees: DA VOLTERRA, BIOASTERInventors: Jean De Gunzburg, Jean-Denis Docquier
-
Patent number: 10982205Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a Verona integron-encoded metallo-?-lactamase (VIM-2) variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.Type: GrantFiled: February 22, 2017Date of Patent: April 20, 2021Assignees: DA VOLTERRA, BIOASTERInventors: Jean De Gunzburg, Jean-Denis Docquier
-
Publication number: 20190048331Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.Type: ApplicationFiled: February 22, 2017Publication date: February 14, 2019Applicants: DA VOLTERRA, BIOASTERInventors: Jean DE GUNZBURG, Jean-Denis DOCQUIER
-
Publication number: 20180369156Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.Type: ApplicationFiled: July 26, 2018Publication date: December 27, 2018Applicant: Da VolterraInventors: Francois LESCURE, Jean DE GUNZBURG
-
Patent number: 10052288Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.Type: GrantFiled: July 5, 2017Date of Patent: August 21, 2018Assignee: DA VOLTERRAInventors: Francois Lescure, Jean De Gunzburg
-
Patent number: 9968562Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.Type: GrantFiled: February 23, 2011Date of Patent: May 15, 2018Assignee: DA VOLTERRAInventors: Francois Lescure, Jean De Gunzburg
-
Publication number: 20130323217Abstract: The present invention relates to a method for the controlled repopulation of the colonic bacterial flora.Type: ApplicationFiled: December 22, 2011Publication date: December 5, 2013Applicants: Da Volterra, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, Universite Paris Diderot-Paris 7Inventors: Antoine Andremont, Jean De Gunzburg
-
Publication number: 20130236944Abstract: The invention relates to methods for inactivating antibiotics in the environment. The invention further relates to the use of a laccase, a lipase or a cellulase for inactivation of antibiotics. It also relates to compositions to decontaminate the polluted environment and to prevent the pollution of the environment by inactivating antibiotics from waste and wastewater effluents before they reach the environment.Type: ApplicationFiled: July 13, 2011Publication date: September 12, 2013Applicant: Da VolterraInventors: Claude Bensoussan, Jean De Gunzburg
-
Patent number: 8388984Abstract: Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, and methods of treatment using the compositions, are disclosed. The compositions are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. Programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and/or colon.Type: GrantFiled: September 14, 2011Date of Patent: March 5, 2013Assignees: Da Volterra, Centre National de la Recherche Scientifique, Assistance Publique—Hopitaux de Paris, Universite Paris Diderot—Paris 7, Universite Paris-SUD 11Inventors: Helene-Celine Huguet, Antoine Andremont, Nicolas Tsapis, Elias Fattal
-
Publication number: 20130052269Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.Type: ApplicationFiled: February 23, 2011Publication date: February 28, 2013Applicant: DA VOLTERRAInventors: Francois Lescure, Jean De Gunzburg
-
Patent number: 8273376Abstract: Drug delivery systems for reducing the quantity of residual antibiotics reaching the colon following oral or parenteral antibiotic therapy, and for delivering metallo-dependent enzymes, and methods of use thereof, are disclosed. The drug delivery systems include pectin beads that encapsulate the active agent (which can be a metallo-dependent enzyme). The pectin is crosslinked with zinc or other divalent cations, and the pectin beads are coated with Eudragit®-type polymers. The delivery of the active agent can be modulated to occur at various pre-selected sites of delivery within the intestinal tract. A stable metallo-dependent enzyme formulation can be delivered to the lower intestine or colon. The use of zinc cations to crosslink the pectin is particularly preferred when the metallo-dependent enzymes are zinc dependent, where other cationic used to gel the pectin beads might adversely affect the activity of such metallo-dependent enzymes.Type: GrantFiled: November 15, 2007Date of Patent: September 25, 2012Assignees: DA Volterra, Assistance Publique-Hopitaux de Paris, Universite Paris Diderot-Paris 7Inventors: Antoine Andremont, Helene Huguet
-
Publication number: 20120058936Abstract: Oral drug delivery formulations which specifically administer antibacterial agents to the ileum, caecum, and/or the colon, without significant administration elsewhere in the gastrointestinal tract, are disclosed. The formulations include, as actives, a combination of a macrolide or aminoglysoside, or quinolone antibacterial and an anti-Gram-negative lipopeptide (polymyxin) antibacterial agent or other peptide antibacterials effective against Gram-negative bacteria. The formulations can be used to treat infections or unwanted colonization in the colon, and to provide effective decontamination of the colonic flora from unwanted or potentially pathogenic bacteria.Type: ApplicationFiled: March 12, 2010Publication date: March 8, 2012Applicants: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, DA VOLTERRA, UNIVERSITE PARIS DIDEROT - PARIS 7Inventors: Antoine Andremont, Jean De Gunzburg, Francois Lescure
-
Patent number: 8106000Abstract: Orally administrable, site-specific (colonic), particulate delivery systems including adsorbents are disclosed. When delivered specifically to the colon, they can remove various substances present in, or as they reach, the colon. Methods of treatment using the delivery systems, and methods of preparing the delivery systems, are also disclosed. The particulate delivery systems are based on adsorbent matrices encapsulated into and/or onto particles, which selectively deliver the adsorbents to the colon. Representative drug delivery devices include pectin beads, which can optionally be crosslinked with metal ions such as zinc and/or calcium. The delivery system protects the adsorbent and prevents its adsorbing effect in the upper gastro-intestinal (GI) tract. When the particles are made from pectin, and the beads are administered to the colon, specific pectinolytic enzymes in the colon degrade the pectin, allowing the adsorbent to be released and to be fully active.Type: GrantFiled: May 18, 2006Date of Patent: January 31, 2012Assignee: Da VolterraInventors: Helene-Celine Huguet, Elias Fattal, Antoine Andremont, Nicolas Tsapis
-
Patent number: 7833765Abstract: The invention concerns multiparticulate galenic formulations for oral administration and designed for colon targeted delivery of active principles selected from the group comprising enzymes capable of inactivating macrolides and the like, enzymes capable of inactivating quinolones and ?-lactamases.Type: GrantFiled: December 29, 2008Date of Patent: November 16, 2010Assignees: Da Volterra, Centre Nationale de la Recherche ScientifiqueInventors: Sandrine Bourgeois, Elias Fattal, Antoine Andremont, Patrick Couvreur
-
Publication number: 20090162339Abstract: The invention concerns multiparticulate galenic formulations for oral administration and designed for colon targeted delivery of active principles selected from the group comprising enzymes capable of inactivating macrolides and the like, enzymes capable of inactivating quinolones and ?-lactamases.Type: ApplicationFiled: December 29, 2008Publication date: June 25, 2009Applicant: DA VOLTERRAInventors: Sandrine Bourgeois, Elias Fattal, Antoine Andremont, Patrick Couvreur
-
Patent number: 7485294Abstract: Forms of colonic delivery suited to be used orally and designed for colonic delivery of active ingredients selected from the group comprising enzymes capable of inactivating macrolide antibiotics and related compounds, enzymes capable of inactivating quinolones, and ?-lactamases.Type: GrantFiled: August 6, 2003Date of Patent: February 3, 2009Assignee: Da VolterraInventors: Sandrine Bourgeois, Elias Fattal, Antoine Andremont, Patrick Couvreur